Novel Recombinant Hemophilia Treatments
Press Release: IDELVION® Approved in Australia
Press Release: IDELVION® Approved in Japan
Press Release: CSL Behring Presents Efficacy Data for AFSTYLA® In Adolescents & Children with Hemophilia A
Press Release: CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at WFH 2016
Press Release: New Data from Recombinant Factor Development Programs at WFH 2016
Press Release: AFSTYLA® Now Available in the U.S.
Press Release: FDA Approves AFSTYLA®
Press Release: FDA Grants IDELVION® 7 Years of Marketing Exclusivity
Press Release: European Commission Approves IDELVION® for Hemophilia B
Press Release: EMA Supports Maintaining Orphan Designation for IDELVION®
Press Release: IDELVION® for Hemophilia B Now Available in the US
Press Release: IDELVION® for Hemophilia B Receives FDA Approval
Press Release: IDELVION® Receives Positive CHMP Opinion
CSL Behring’s recombinant factor development pipeline is built on its strength in protein research and development and scientific expertise in bleeding disorders, coupled with a long-standing commitment to the bleeding disorders community.
hemophilia A is a novel recombinant single-chain factor VIII (FVIII) construct specifically designed for greater molecular stability.
rVIII-SingleChain Fact Sheet
Depiction of rVIII-SingleChain molecule
hemophilia B is CSL Behring’s long-acting recombinant fusion protein linking coagulation factor IX with albumin. CSL Behring specifically engineered rIX-FP to extend the half-life of recombinant factor IX through genetic fusion with recombinant albumin. CSL Behring selected albumin as its recombinant genetic fusion partner for its coagulation factor proteins due to its long physiological half-life.
rIX-FP Fact Sheet
Depiction of rIX-FP molecule
These two potential therapies underscore CSL Behring’s promise to save lives and improve the quality of life for people with bleeding disorders and other serious medical conditions.
"CSL Behring’s rIX-FP for Hemophilia B"
This video highlights CSL Behring’s product promise to the hemophilia B community. With a company history spanning more than 100 years, CSL Behring has always been motivated by innovation, and is the original expert in bleeding disorders.
Tim’s Story – Outdoor Adventurer Living With Hemophilia
New father and hemophilia A patient Tim Grams enjoys the Colorado outdoors. See how Tim isn't letting this hereditary blood disorder keep him from hiking Dinosaur Ridge or mountain biking at Red Rocks Park.
"Hemophilia Won't Hold Me Back"
Each year, kids with hemophilia or von Willebrand disease in the U.S. come together at the Gettin’ in the Game℠Junior National Championship (JNC) program. Sponsored by CSL Behring, the JNC gives kids the opportunity to form life-long connections, learn how to safely and confidently play sports, and compete in a golf or baseball competition.
“Living with von Willebrand Disease: Jordan’s Story”
College student and Gettin' in the Game℠: Junior National Championship (JNC) mentor Jordan Swoape talks about living with von Willebrand disease and shares an inspirational message to empower others living with bleeding disorders.
Kristin's Story: Living Life to the Fullest Despite VWD
Wife, mother and caregiver Kristin Prior was diagnosed with von Willebrand Disease (VWD) after learning her son was born with the hereditary bleeding disorder. Learn about Kristin's active life despite the challenges VWD can pose and how she partners with CSL Behring to help others diagnosed with a bleeding disorder.